HMOX1 and pancreatitis: Administration of bilirubin or CO protects against pancreatitis by inhibiting NF-κB inflammatory responses and increasing the Nrf2/HO-1 pathway [112], or by impairing the recruitment of pro-inflammatory immune cells [113], respectively.